# Wells Fargo & Company

Type: Company (WFC)

Source: GetYourBrief — https://getyourbrief.com/entity/wells-fargo-company
Canonical HTML page: https://getyourbrief.com/entity/wells-fargo-company

## Timeline

- **2026-08-14**: Dividend Payment Date — Quarterly dividend paid to shareholders of record July 24.
- **2026-08-08**: Wall Street Zen cuts STAG and ZVIA to Sell — Wall Street Zen downgraded both Stag Industrial and Zevia PBC from hold to sell in weekend research notes.
- **2026-08-05**: ZVIA reports Q2 results — Zevia PBC reported EPS of -$0.03, hitting consensus, and revenue of $45.00 million versus a $44.21 million estimate.
- **2026-07-31**: Weiss reiterates buy on STAG; Baird sets $138 target — Weiss Ratings reiterated a buy (b-) rating on Stag Industrial, while Robert W. Baird set a $138.00 target price.
- **2026-07-28**: STAG reports Q2 earnings miss — Stag Industrial reported EPS of $0.28, missing the consensus estimate of $0.65 by $0.37; revenue was approximately $224 million.
- **2026-07-24**: Dividend Record Date — Shareholders of record qualify for $0.77 quarterly dividend.
- **2026-07-22**: Q2 Earnings Release — Kaiser Aluminum reports EPS $5.53, beats estimates by $2.87; revenue $1.26B surpasses $1.12B estimate.
- **2026-07-17**: Weiss Ratings upgrades ZVIA within sell range — Weiss Ratings raised shares of Zevia PBC from a sell (e+) rating to a sell (d-) rating.
- **2026-07-16**: Barclays raises STAG target but stays Underweight — Barclays boosted its price objective on Stag Industrial from $38.00 to $41.00 and maintained an underweight rating.
- **2026-07-09**: Wells Fargo Reaffirms Underweight — Wells Fargo reiterates underweight rating, sets $158 price target.
- **2026-07-08**: Wells Fargo Cuts Target to $70 — Wells Fargo & Company lowers Freshpet’s price target from $75.00 to $70.00, keeping an Overweight rating, implying 28.42% upside.
- **2026-07-08**: UBS Lifts Price Target — UBS raises Kaiser Aluminum target to $179 from $176, maintains neutral rating.
- **2026-07-01**: Bank of America Lowers Target — Bank of America reduces its price target from $75.00 to $70.00 and maintains a Neutral rating.
- **2026-06-24**: Stock surges 8.6% — Price hit $14.43 during session, closing at $14.38 on very light volume.
- **2026-06-15**: Piper Sandler Stays Overweight — Piper Sandler reaffirms an Overweight rating on Freshpet shares.

## Recent coverage (20 stories, network-wide)

### STAG Downgraded to Sell as Price Sits 38% Below $50.50 Target
2026-08-13 00:19:12 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen cut Stag Industrial to sell, putting a fresh bearish tilt on a REIT whose shares opened at $36.68 versus a $50.50 consensus target. The same firm also downgraded Zevia PBC as its major shareholder trimmed a 15.87% stake.
Full story: https://getfinancebrief.com/story/stag-industrial-wall-street-zen-sell-downgrade

### SoFi Stock Surges 3.7% to $18.70 Despite 5 Analyst Target Cuts – What’s Next?
2026-08-12 13:34:09 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

SoFi Technologies shares jumped 3.7% on August 4, 2026, even as multiple analysts slashed price targets, creating a tension between market momentum and cautious research. With a PE of 38.96, beta of 2.17, and consensus Hold rating, the fintech’s next move hinges on whether profitability can catch up with valuation.
Full story: https://getfinancebrief.com/story/sofi-stock-surges-3-7-percent-analyst-target-cuts

### Wells Fargo Slashes CHKP Target to $130: 13.01 P/E and Consensus Hold Demand Attention
2026-08-12 13:16:01 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wells Fargo lowered Check Point's target to $130, highlighting a divided analyst community with an average target of $149.48. The stock's depressed valuation and low beta present a potential value opportunity against high-growth cyber peers.
Full story: https://getfinancebrief.com/story/chkp-price-target-130-finance-analysis

### HC Wainwright Cuts Circle (CRCL) to $104, Still Sees 64% Upside
2026-08-07 01:20:20 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

HC Wainwright and Needham lowered price targets on Circle Internet Group but maintained Buy ratings as analysts remain split on the stablecoin issuer. The stock trades at $63.48, far below the consensus target of $100.06, highlighting both opportunity and risk.
Full story: https://getfinancebrief.com/story/circle-crcl-price-target-cut-finance

### USDC Issuer Circle (CRCL) Sees Targets Slashed, Yet 100% Upside Possible
2026-08-07 01:20:09 · Sector: crypto · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Two investment banks cut their price targets on Circle Internet Group, the firm behind the USDC stablecoin, citing near-term headwinds—but both maintained Buy ratings with triple-digit upside potential. The stock’s deep pullback from its $189 high reflects broader crypto market caution.
Full story: https://getcryptobrief.com/story/circle-usdc-price-target-crypto

### Smith Douglas Homes Leaps 8.6%: PropTech Industry Implications
2026-08-04 20:29:39 · Sector: proptech · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The 8.6% jump in Smith Douglas Homes stock to $14.38, despite analyst caution and low volume, may signal shifting sentiment in the homebuilding sector that directly impacts PropTech adoption and innovation. For real estate technology stakeholders, the move underscores the interconnectedness of traditional construction and emerging digital solutions.
Full story: https://getproptechbrief.com/story/smith-douglas-homes-8-6-surge-proptech

### Wabtec FY26 EPS $10.60-$10.90, Moody's $16.50-$17.00: Both Miss Consensus
2026-07-23 02:24:25 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wabtec guided revenue between $12.3-$12.6B and EPS slightly below the Street, while Moody’s EPS range also came in under estimates. Analysts remain constructive with moderate buy ratings and double-digit upside targets for both stocks.
Full story: https://getfinancebrief.com/story/wabtec-moodys-fy26-guidance-analysis

### Kaiser Aluminum EPS Beat by $2.87: Revenue Hits $1.26B, Shares Dip to $164.32
2026-07-23 00:53:05 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Kaiser Aluminum's Q2 2026 EPS of $5.53 blasts past estimates by 108%, with revenue reaching $1.26B. Despite the beat, the stock slipped 0.03% to $164.32 amid insider sales and mixed analyst targets. The $0.77 quarterly dividend and strong liquidity ratios offer some reassurance.
Full story: https://getfinancebrief.com/story/kaiser-aluminum-earnings-beat-eps-287-revenue-126b

### ResMed Faces $270.64 Consensus Target Amid Analyst Divide on Sleep Device Demand
2026-07-10 14:15:23 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Analyst downgrades reflect growing fears that GLP-1 weight loss drugs could erode the sleep apnea device market, even as ResMed’s financials stay solid. The contrast between a $225 low target and $321 high target underscores sector uncertainty.
Full story: https://gethealthbrief.com/story/resmed-analyst-target-sleep-apnea-demand

### ResMed Targets Drop to $225 at Wells Fargo; Upside Remains at +23.2%
2026-07-10 14:15:12 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wells Fargo’s $225 target is the lowest among major banks, yet ResMed’s average analyst target of $270.64 implies a 23.2% upside. Markets weigh defensive balance sheet qualities against emerging therapeutic competition.
Full story: https://getfinancebrief.com/story/resmed-stock-analyst-target-cuts-wells-fargo

### ResMed’s $270.64 Consensus Hides a 30% Spread in Analyst Targets
2026-07-10 14:14:59 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Biotech and life sciences investors face a paradox: ResMed’s stalwart medical device business is underpinned by low debt and high margins, yet analyst targets range from $225 to $321 as GLP-1 therapies threaten its patient base.
Full story: https://getbiobrief.com/story/resmed-analyst-divide-biotech-investment

### Wells Fargo Cuts Freshpet Target to $70, Still Sees 28% Upside
2026-07-09 13:12:08 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wells Fargo lowered its price target on Freshpet to $70 from $75 while maintaining an Overweight rating, implying the stock is undervalued by 28%. The market remains skeptical with FRPT trading at $54.51, well below the consensus analyst target of $74.25. Analysts overall rate the pet food company a Moderate Buy, despite a string of recent target cuts.
Full story: https://getfinancebrief.com/story/wells-fargo-cuts-freshpet-target-70-upside

### Raleigh Capital boosts VZ stake 33.7% – a $3.13M bet on Verizon's 6% yield
2026-07-06 07:06:29 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Raleigh Capital Management increased its Verizon position by a third in Q1 2026, joining other small institutional buyers. Despite VZ's recent price weakness and mixed analyst views, the defensive telecom's high dividend yield and 62% institutional ownership remain draws for income-focused portfolios.
Full story: https://getfinancebrief.com/story/raleigh-capital-boosts-vz-stake-33-percent

### AI Cloud Stock CoreWeave Tumbles 48% as Insider Sells $19M; Debt Ratio Hits 3.68
2026-07-05 21:37:20 · Sector: ai · Sentiment: Neutral · Impact: 5/10 · Sources: 4

CoreWeave, a vital GPU cloud provider for AI workloads, saw its stock plunge 48% from its high as a top insider sold $19M in shares. With revenue surging 111.6% but the company deeply leveraged at 3.68 D/E, the AI infrastructure boom faces a reality check.
Full story: https://getaibrief.com/story/coreweave-ai-stock-insider-sell-debt

### CoreWeave Insider Cashes Out $19M as Post-IPO Stock Slides 48% from $166 High
2026-07-05 21:36:13 · Sector: startups · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Brannin Mcbee, a top CoreWeave insider, sold $19M worth of shares across two days under a 10b5-1 plan, reducing his stake by a combined 50.67% as the stock sits 48% below its peak. The sales highlight the delicate dance of founder and executive liquidity in the AI infrastructure startup space.
Full story: https://getstartupbrief.com/story/coreweave-insider-sells-19m-startups

### Instacart Put Options Spike 144% to 8,267 Contracts Amid E-Commerce Jitters
2026-07-05 14:11:10 · Sector: retail · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Maplebear (Instacart) saw an unusual surge in put option volume on Monday, with 8,267 contracts traded—a 144% increase—signaling bearish bets on the grocery delivery giant. Despite strong revenue growth and raised analyst targets, the options activity hints at market caution. Here's what it means for retail and e-commerce investors.
Full story: https://getretailbrief.com/story/instacart-put-options-spike-144-ecommerce

### Wells Fargo Downgrades O-I Glass to Equal Weight Amid Packaging Headwinds
2026-03-20 14:18:39 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wells Fargo has lowered its rating on O-I Glass (NYSE: OI) from Overweight to Equal Weight, signaling a more cautious stance on the glass packaging giant. The move reflects broader industry challenges and a shift in analyst expectations regarding the company's near-term growth trajectory.
Full story: https://getfinancebrief.com/story/oi-glass-wells-fargo-downgrade-analysis

### AxoGen Surges as Wells Fargo Issues Rare 'Strong-Buy' Rating Upgrade
2026-02-21 01:12:47 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

AxoGen (NASDAQ: AXGN) has received a major boost from Wall Street as Wells Fargo upgraded the nerve-repair specialist to a 'Strong-Buy' rating. The upgrade follows a significant price target hike from Jefferies, signaling a robust consensus on the company's growth potential in the medical technology sector.
Full story: https://getfinancebrief.com/story/axogen-axgn-wells-fargo-strong-buy-upgrade

### Wells Fargo Upgrades AxoGen to Strong-Buy as Nerve Repair Market Gains Momentum
2026-02-21 01:12:15 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wells Fargo has upgraded AxoGen (NASDAQ: AXGN) to a 'Strong-Buy' rating, reflecting growing institutional confidence in the company's leadership in peripheral nerve repair. The upgrade follows a significant price target increase from Jefferies and a reaffirmed 'Market Outperform' rating from Citigroup.
Full story: https://getbiobrief.com/story/axogen-wells-fargo-upgrade-nerve-repair-market

### Wells Fargo Upgrades AxoGen to Strong-Buy as Nerve Repair Market Gains Momentum
2026-02-21 01:11:42 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

AxoGen (NASDAQ: AXGN) has received a significant rating upgrade to "Strong-Buy" from Wells Fargo, signaling robust institutional confidence in the peripheral nerve repair specialist. This move, coupled with price target hikes from Jefferies and positive outlooks from Citigroup, underscores a bullish sentiment for the company's clinical and commercial trajectory.
Full story: https://gethealthbrief.com/story/axogen-wells-fargo-strong-buy-upgrade

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.